Time filter

Source Type

Basel, Switzerland

Ondondo B.,University of Oxford | Brennan C.,Huntington Life science | Nicosia A.,Okairos Inc. | Crome S.J.,Huntington Life science | Hanke T.,University of Oxford
Vaccine | Year: 2013

Background: The systemic toxicity of three candidate HIV-1 vaccines plasmid pSG2.HIVconsv DNA (D), ChAdV63.HIVconsv (C) and MVA. HIVconsv (M) expressing chimeric immunogen derived from the most conserved regions of the HIV-1 proteome was evaluated in two repeat-dose studies in the male and female BALB/c mice. Methods: In study UNO011, mice received three doses of 2×107 plaque-forming units of MVA. HIVconsv vaccine (MMM). In study UNO012, mice received 3 doses of 50μg of pSG2.HIVconsv DNA followed by a single dose of 5.95×109 virus particles of ChAdV63.HIVconsv vaccine (DDDC). Similarly constituted control groups received the vehicle alone (phosphate buffered saline) at the same volume-dose. All vaccines were administered by intramuscular needle injection into the right hind limb at 14-day intervals and animals were sacrificed 7 days after the last dose. Assessment of local and systemic toxicity was made. Induction of HIV-1-specific responses was confirmed. Parameters assessed included clinical condition, body weight, food consumption, ophthalmoscopy, haematology, blood chemistry, organ weight and macroscopic and microscopic pathology. Results: In both studies, treatment with the candidate vaccines elicited strong HIV-1-specific T-cell responses. The vaccine treatment was well-tolerated without any adverse systemic toxicological changes. The local toxicity findings observed in these studies were consistent with the predicted response to a vaccine/substance administration by intramuscular injection. Conclusions: The three novel anti-HIV-1 vaccines were well tolerated when administered by intramuscular injection to BALB/c mice. These results supported an application for authorisation by the Medicines and Healthcare Products Regulatory Agency of the UK to test these vaccines for the first time in phase I clinical trials in healthy both uninfected subjects and HIV-1-infected patients stable on antiretroviral treatment. © 2013 The Authors.

Okairos Inc. | Date: 2011-12-30

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).

Okairos Inc. and Thegovernmentof The Unitedstatesof America Asrepre Sentedby Thesecretaryofthedept.Ofhealth&Humanser | Date: 2011-04-15

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

News Article | August 28, 2014
Site: www.fiercebiotech.com

When GlaxoSmithKline ($GSK) bought out Okairos last year for $325 million, the platform vaccine technology it acquired was focused on a slate of early-stage development programs covering a range of targets like hepatitis C, malaria and tuberculosis. But in recent weeks the international frenzy over a serious outbreak of Ebola in West Africa has pushed that program to center stage. And today the pharma giant--one of the world's top vaccine players--has joined hands with a global consortium of agencies, nonprofits and investigators to compress a years-long development effort into a matter of weeks as the outbreak worsens. Initially, GSK officials had sounded distinctly skeptical about whether the vaccine could be ready in time to help contain the outbreak. But this morning there was a distinct can-do attitude in its approach to the crisis. Using a $4 million grant, Oxford's Adrian Hill will launch a Phase I safety test in about two weeks, once it locks up the necessary paperwork. Hill's study in volunteers will take place alongside separate trials at the National Institute of Allergy and Infectious Diseases in the U.S. And after it's been run through small studies on the healthy volunteers, a green light from regulators would allow investigators to immediately broaden the work to an at-risk population in Gambia and Mali to evaluate whether or not it can contain the virus. While investigators are testing the vaccine in volunteers, GSK plans to simultaneously ramp up production of 10,000 doses, prepping for a quick vaccination campaign. If all goes well, GSK says the early-stage study can be wrapped in 3 months--virtual light speed in the pharma industry. The consortium is gambling on next-gen vaccine technology that was spun out of Merck back in 2007. Inspired by the research of Okairos founder Riccardo Cortese, investigators have been using deactivated chimp viruses to deliver genetic material to cells, triggering a powerful CD8 T cell response--an immune response that can be directed squarely at an invader like Ebola. Most of the attention for Okairos, a 2012 Fierce 15 winner, had been focused on its hepatitis C vaccine work. The lightning quick effort comes as the WHO notes that the number of people afflicted with the deadly Ebola virus could triple in coming months, noting that 40% of all reported cases have occurred in the past three weeks. The epidemic could ultimately hit more than 20,000 people as health officials try to end the outbreak in the next 6 to 9 months. GSK R&D chief Moncef Slaoui sounded a note of cautious optimism in his statement. "Today's announcement shows how private and public partners can pull together to respond to this critical public health emergency," said Slaoui. "Developing a new vaccine is complex with no guarantees of success and it's still early days for our Ebola vaccine candidate. But we are encouraged by progress so far and will do the best we can, along with WHO and our partners, to speed up development and explore ways in which the vaccine could contribute to the control of this or future Ebola outbreaks." Related Articles: Global fear of Ebola outbreak stokes a frenzy of new R&D, production plans Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program? FDA switches course on Tekmira drug as Ebola panic triggers policy review

The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve, the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.

Discover hidden collaborations